Welcome to the Gilson Resource Center
Since Gilson invented the variable volume pipette 45 years ago, we have been an industry leader in liquid handling innovation, helping scientists by making lab life easier and being more productive. Gilson sees the next big innovation revolution around advances in the lab enabled by connected, smart devices containing technologies referred to as the Internet of Things (IoT). We sat down with Steve DeCabooter, Director of Product Information Platforms at Gilson, to discuss the growing role of the IoT in the laboratory, and how Gilson’s connected pipettes will contribute to this trend and infuse research with greater traceability and verifiability.
Cannabidiol (CBD) is a non-psychotropic cannabinoid from the Cannabis sativa L. (Cannabaceae) plant. Researchers have shown that CBD’s medicinal properties may be of use for treating a variety of conditions including pain, inflammation, epilepsy, and cancer.1,2 Recently, the US Food and Drug Administration (FDA) approved the first cannabis-derived drug (Epidiolex®) to treat children with rare forms of epilepsy.
As globalized food trade has become more common in recent years, improved screening methods combined with food inspection investigations have put a large amount of pressure on the food and beverage industry to improve quality assurance and control. This pressure led to the FDA Food Safety Modernization Act (FSMA), which aims to ensure the U.S. food supply is safe by shifting the focus of federal regulators from responding to contamination to preventing contamination.
High-Performance Liquid Chromatography (HPLC) is the industry standard for cannabinoid extraction, but Centrifugal Partition Chromatography (CPC) offers a cost-effective and environmentally friendly alternative with comparable yields and purity. In this article, we describe:
- How each method works
- What differences to take into consideration during cannabis testing
- How to choose the right method for your purification needs
Mass spectrometry was once a technology that only a few knew how or could afford to use, and is now moving into more mainstream analytical environments. This move requires changes in instrumentation design, making it easier to use and maintain, while improving productivity and lowering operational and maintenance costs. See how a new breed of mass detectors are meeting this need through miniaturization.
We interviewed Dr. Francesco Fiorentino, Founder and CSO of Kitos Biotech, to discuss his lab and its transition to automated liquid handling. Learn more about their story and how they have gained a competitive advantage in the market of preclinical research.